We are always researching new frontiers in ultrasound technology. Read below for our latest findings and insights.
Francois Michelon, CEO of ENDRA Life Sciences Inc., explains how ENDRA is leading early detection of liver diseases and issues with existing tools’ diagnostic and accessibility properties.Watch the video >
Francois Michelon, CEO of ENDRA Life Sciences Inc., discusses childhood obesity and the risks of NAFLD.Watch the Video >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ technology can help detect and monitor NAFLD-NASH caused by hepatitis.Watch the video >
Renaud Maloberti, CCO of ENDRA Life Sciences Inc., talks about the importance of early diagnosis and access to healthcare.Watch the video >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about how TAEUS™ is focused on early detection of liver disease by measuring liver fat.Watch the video >
Francois Michelon, CEO of ENDRA Life Sciences Inc., talks about the significance of CE Mark certification.Watch the video >
ENDRA Life Sciences is active in external research collaborations with both academic and private research organizations. The policy of ENDRA Life Sciences is to limit the amount of indirect costs associated with any research funding it provides to any research organizations, to 15% through Sponsored Research Agreements, Collaborative Research Agreements, or other research related agreements.
ENDRA shall not agree to overhead costs, indirect costs or other research associated costs above fifteen percent (15%) of the cost of the contracted research amount.
ENDRA operates a Quality Management System which complies with the requirements of ISO 13485:2016 & EN ISO 13485:2016 for the following scope:
Certificate number: MD 697226
Effective Date: 2019-04-02
Expiry Date: 2022-04-01